SLNO
NASDAQ HealthcareSoleno Therapeutics, Inc. - Common Stock
Biotechnology
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
๐ Market Data
| Price | $52.87 |
|---|---|
| Volume | 1,207,822 |
| Market Cap | 2.73B |
| Beta | -2.810 |
| RSI (14-Day) | 64.2 |
| 200-Day MA | $54.23 |
| 50-Day MA | $42.73 |
| 52-Week High | $90.32 |
| 52-Week Low | $29.43 |
| P/E Ratio | 135.56 |
| Forward P/E | -23.29 |
| Price / Book | 6.14 |
๐ฏ Investment Strategy Scores
SLNO scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (71/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SLNO in your text
Paste any article, transcript, or post โ the tool will extract SLNO and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.